IS PERIOSTIN USEFUL AS A BIOMARKER FOR FIBROUS DYSPLASIA?

MASTAGLIA SR; BONANNO MARINA SOLEDAD; DOLORES GÓMEZ GLORIOSO; GONZÁLEZ, DIANA; ROSANA GAINOTTI; OLIVERI BEATRIZ; WALTER TETZLAFF; CANDELA FERNÁNDEZ

Actualizaciones en Osteología

AAOMM

Lugar: Capital Federal; Año: 2022

1669-8975

Fibrous dysplasia (FD) is an infrequent nonhereditary bone disease caused by a somaticmutation of the GNAS gene. Periostin is anovel marker that increases during tissuehealing and fibrous or inflammatory diseases.We conducted an exploratory case-controlstudy to evaluate sensitivity of periostin asa biomarker of FD. The study comprised 15patients with FD, and healthy age- and sexmatched subjects (controls). Serum periostinlevels were assessed and comparisonswere established between FD patients andcontrols, and between patients with themonostotic and the polyostotic form of FD.No statistically significant differences in serumperiostin levels were observed between thecohort of FD patients studied here and thecontrol group (FD: 51.1±10ng/ml vs. control:44.2±15ng/ml; p=0.15), or between the clinicalforms of FD (polyostotic: 51.8±9.1ng/ml vs.monostotic: 49.6±13 ng/ml; p=0.66). A subanalysis performed to compare serum levelsof periostin in FD patients with and withouta history of fractures showed no statisticallysignificant differences [fracture patients(n=4): 41.2±17ng/ml vs. non-fracture patients(n=11): 49.9±11 ng/ml; p=0.47].Lastly,sensitivity of periostin as a biomarker of FDwas analyzed, and was found to have lowsensitivity to estimate disease activity [ROCcurve; cut-off points: 39.625(0.867-0.467)]. Toconclude, in the cohort of FD patients studiedhere, periostin serum levels did not differsignificantly from those of the control groupor between the two forms of the disease, andshowed low sensitivity as a biomarker of thedisease